MedTrace Logo

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-06-22

No results posted yet for this study

Summary

We propose a 3-arm RCT to determine the efficacy of hydroxychloroquine or azithromycin in treating mild to moderate COVID-19 among Veterans in the outpatient setting.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.

DRUG

Azithromycin

Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.

DRUG

Placebo oral tablet

Placebo in pill packs identical to study drugs

Sponsors & Collaborators

  • San Francisco VA Health Care System

    collaborator FED

  • Salomeh Keyhani MD

    lead FED

Principal Investigators

  • Salomeh Keyhani, MD MPH · San Francisco VA/University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
216 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2021-03-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04363203 on ClinicalTrials.gov